CD137 CRISPR/Cas9 KO Plasmid (h): sc-405068
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD137 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CD137 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD137 Antibody (BBK-2): sc-58947
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD137 CRISPR/Cas9 KO Plasmid (h) | sc-405068 | 20 µg | $397.00 |
Overview
TNFRSF9 encodes CD137 (4-1BB), an inducible co-stimulatory receptor of the TNF receptor superfamily expressed on activated T cells and other immune subsets. Upon engagement, CD137 recruits TRAF adaptors to stimulate NF-κB and MAPK signaling, promoting cell survival, proliferation, cytokine production, and metabolic reprogramming during immune responses. This pathway contributes to regulation of cytotoxic lymphocyte activity, dendritic cell function, and inflammatory signaling within the tissue microenvironment. Dysregulated TNFRSF9/CD137 signaling has been associated with altered immune activation states observed in cancer immunology, chronic infection, and autoimmune or inflammatory disease research contexts.
CD137 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the TNFRSF9 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the TNFRSF9 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the TNFRSF9 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CD137 protein expression.
This CRISPR knockout system enables efficient generation of TNFRSF9-deficient cell models for investigation of CD137 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting TNFRSF9 exon(s) critical for CD137 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple TNFRSF9 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CD137 CRISPR/Cas9 KO Plasmid (h) and CD137 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the TNFRSF9 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CD137 HDR Plasmid (h) and CD137 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by TNFRSF9 homology arms to support homology-directed repair at defined TNFRSF9 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.